Roche, Mississauga, ON, Canada, has announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for Xenical (orlistat), as an adjunct to other anti-diabetic medications for the treatment of type 2 diabetes in patients who are overweight or obese. This is important because almost 90 percent of patients with type 2 diabetes are overweight or obese and weight is the most important modifiable risk factor in patients with type 2 diabetes. In Canada, a submission regarding type 2 diabetes will be made to Health Canada in the near future.

cialis - check it

tramadol - check it

viagra - check it

levitra - check it

phentermine - check it

xenical - check it